Formulations and methods for treating rhinosinusitis
View Patent ↗The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
1. A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, comprising an aqueous suspension of a steroidal anti-inflammatory, said formulation comprising:
a) a therapeutically effective amount of the steroidal anti-inflammatory, wherein the steroidal anti-inflammatory comprises beclomethasone having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.3 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.55 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 1.8 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 2.7 microns; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg, and wherein the formulation is suitable for intranasal administration.
2. The formulation of claim 1 , wherein the formulation comprises about 1 to about 700 mcg of a steroidal anti-inflammatory, and wherein the steroidal anti-inflammatory further comprises fluticasone.
3. The formulation of claim 1 , wherein the formulation comprises an aqueous suspension that is deliverable via an atomizing device.
4. The formulation of claim 3 , wherein the atomizing device comprises a metered dose spray pump.
5. The formulation of claim 1 , wherein the formulation further comprises a liquid propellant.
6. The formulation of claim 1 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.
7. The formulation of claim 1 , further comprising about 20 to about 70 mg of fluconazole or itraconazole.
8. The formulation of claim 7 , wherein the formulation comprises about 25 to about 50 mg of fluconazole or itraconazole.
9. The formulation of claim 1 , wherein the formulation comprises about 7.5 to about 15 mg of amphotericin β.
10. The formulation of claim 1 , further comprising an antibiotic, antiviral agent, or combinations thereof.
11. The formulation of claim 10 , wherein the antibiotic is one or more of Amikacin, Azithromycin, Aztreonan, Cefazolin, Cefepine, Cefonicid, Cefaperazone, Cefotaxime, Cefotetan, Cefoxitin, Ceftazidime, Ceftizoxime, Ceftriaxone, Cefuroxime, Cephapirin, Ciprofloxacin, Clindamycin, Doxycycline, Erythromycin Lactobionate, Gentamicin, Kanamycin, Linezolid, Mezlocillin, Mupirocin, Nafcillin, Netilmicin, Neomycin, Oxacillin, Paromomycin, Piperacillin, Streptomycin, Ticarcillin, Tobramycin, or Vancomycin.
12. A nasal spray formulation comprising:
an aqueous suspension having
a) about 0.005% to about 5% by weight of a steroidal anti-inflammatory, the steroidal anti-inflammatory comprising beclomethasone having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.3 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.55 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 1.8 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 2.7 microns; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg, and wherein the formulation is suitable for intranasal administration.
13. The nasal spray formulation of claim 12 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.
14. The nasal spray formulation of claim 12 , further comprising neomycin sulfate.
15. A method of treating fungus-induced rhinosinusitis in a mammal, said method comprising the steps of applying to the mammal's nasal-paranasal mucosa a formulation comprising:
a) a therapeutically effective amount of a steroidal anti-inflammatory, wherein the steroidal anti-inflammatory comprises beclomethasone having the following particle size distribution profile:
i. about 10% of the steroidal anti-inflammatory particles have a particle size of less than 0.3 microns;
ii. about 25% of the steroidal anti-inflammatory particles have a particle size of less than 0.55 microns;
iii. about 50% of the steroidal anti-inflammatory particles have a particle size of less than 1.2 microns;
iv. about 75% of the steroidal anti-inflammatory particles have a particle size of less than 1.8 microns; and
v. about 90% of the steroidal anti-inflammatory particles have a particle size of less than 2.7 microns; and
b) an antifungal agent, wherein the amount of the antifungal agent is from about 0.5 to 150 mg, and wherein the formulation is suitable for intranasal administration.
16. The method of claim 15 , wherein the antifungal agent is amphotericin β, fluconazole, itraconazole, or combinations thereof.
17. The method of claim 15 , formulation is applied via a metered-dose, manual pump spray unit.
18. The method of claim 17 , wherein the formulation is administered to the mammal as one spray in each nostril from 1 to about 10 times per day.